A retrospective, single-centre study of clinical markers associated with the absence of efficacy of CKI used as monotherapy in NSCLC
Latest Information Update: 30 Sep 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Brain metastases; Cancer metastases; Liver metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 01 Oct 2020 Results published in the Journal of Cancer Research and Clinical Oncology
- 30 Sep 2020 New trial record